Alkermes | Investor Conference Presentation Deck

Slide schematic 5/5

disclaimer 1/1 image 1/1 list 2/2 title 1/1

Components 5

disclaimer infographic bullet bullet headline

Tools 1

list/bullet: Demonstrated durable and deepening responses in high unmet need populations; Monotherapy activity in prior anti-PD-(L)1 treated melanoma and renal cell carcinoma; Combination activity with pembrolizumab in a

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 0

∅

No frameworks

No framework match is anchored to this slide.

Find anything

The slide uses a human body diagram to map tumor types treated with monotherapy vs. combination therapy.